Zika Virus
22
0
0
17
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 22 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
41%
7 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (22)
Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults
Neurodevelopmental Outcomes in ZIKV-Exposed Children
Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua
Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
Cohort of Patients Infected by an Arbovirus
Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)
ZIKAlliance Pregnant Women Cohort
ZIKAlliance Natural History Study
ZIKAlliance Children Cohort (ZIKAllianceCH)
Prospective Cohort Study of HIV and Zika in Infants and Pregnancy
Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil
Persistence of Zika Virus in Semen After Acute Infection
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)